DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD SELECTS PHILIP S. SCHEIN, M.D.
DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD SELECTS PHILIP S. SCHEIN, M.D. WEST CONSHOHOCKEN, Pa., June 29 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) is proud to announce that its chairman and chief executive officer, Philip S. Schein, M.D., is the recipient of the Delaware Valley's Entrepreneur of the Year Award in the "Emerging Company" category. As the founder of the U.S. Bioscience five years ago, the award recognizes Dr. Schien's scientific and management contributions to the establishment of a highly successful company dedicated to improving the quality of life and care for cancer patients. In accepting the award, Dr. Schein said: "The creation of U.S. Bioscience has provided an opportunity to make an important impact on the treatment of cancer patients on a worldwide basis." The Entrepreneur of the Year competition seeks to identify superior performances among entrepreneurial companies. Thirty finalists were selected in eight categories among companies scattered throughout the Delaware Valley. Prior to joining U.S. Bioscience, Dr. Schein was vice president of Worldwide Clinical Research and Development, Smith Kline & French Laboratories. Earlier, he served as scientific director of the Vincent T. Lombardi Cancer Research Center at the Georgetown University School of Medicine in Washington. He also served as senior investigator and head of the clinical pharmacology section of the medicine branch, National Cancer Institute, Bethseda, Md. Dr. Schein has authored over 350 articles and texts relating to basic and clinical cancer research and drug development. He served as president of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncology Drugs Advisory Committee, where he received the commissioner's Special Citation and the Harvey W. Wiley Medal. U.S. Bioscience's portfolio includes a broad spectrum of drugs for cancer and AIDS, including four products in the late stages of development. One compound, altretamine, is marketed under the name Hexalen in the United States for patients with advanced, refractory cancer of the ovary. /delval/ -0- 6/29/92 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/ CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: PER
RM -- SJ003 -- 4714 06/29/92 12:21 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 29, 1992|
|Previous Article:||MAGNETECH EXTENDS WARRANT EXERCISE DATE ADDITIONAL 31 DAYS|
|Next Article:||DELL CUTS PRICES, EXPANDS SERVICES AND SUPPORT AND ADDS NEW LOW-COST LINE OF PCs; CAPITALIZES ON OPERATING EFFICIENCIES TO OFFER MORE VALUE|